Clinical Trials Logo

Ovarian Neoplasms clinical trials

View clinical trials related to Ovarian Neoplasms.

Filter by:

NCT ID: NCT03245736 Completed - Prostate Cancer Clinical Trials

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Start date: August 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.

NCT ID: NCT03235648 Recruiting - Ovarian Cancer Clinical Trials

Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

Evaluation of surgical excision of cardiophrenic lymph nodes in patients with advanced ovarian cancer

NCT ID: NCT03229122 Completed - Ovarian Cancer Clinical Trials

Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA

CHARLOTTE
Start date: December 26, 2016
Phase:
Study type: Observational [Patient Registry]

The multi-centered, cross-sectional investigations shall be conducted in this study with the objective of identifying the ownership ratio of gBRCAm on the newly diagnosed patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer in Japan.

NCT ID: NCT03219242 Enrolling by invitation - Ovarian Cancer Clinical Trials

Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology

CAIMAN
Start date: June 30, 2016
Phase: N/A
Study type: Interventional

Longitudinal prospective study on primary debulking surgery including bowel resection in advanced stage ovarian cancer patients using Caiman® technology

NCT ID: NCT03206645 Completed - Ovarian Cancer Clinical Trials

Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy

PTC-001
Start date: August 28, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label Phase Ib dose-escalation study to determine the safety, tolerability, and pharmacokinetics of Unesbulin when combined with and following conventional chemotherapy and as maintenance therapy as a capsule (weight based dosing) and a tablet (fixed dosing) in women with epithelial ovarian, fallopian tube or primary peritoneal cancer which is previously untreated.

NCT ID: NCT03206216 Terminated - Pain, Acute Clinical Trials

Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN

Start date: August 4, 2017
Phase: N/A
Study type: Interventional

This clinical trial studies how well Diode laser fiber type Selective Stimulator (DLss) works in predicting pain development in patients with ovarian cancer who are receiving chemotherapy. Stimulating of the pain nerve fibers in the skin with laser light stimulation may help to predict whether a patient will develop painful peripheral neuropathy, correlate with the severity of neuropathy during and after chemotherapy treatment, and may help to explain the mechanisms of chemotherapy-induced neuropathic pain (CIPN).

NCT ID: NCT03206047 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: November 8, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized phase I/IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1401 vaccine may enhance the expression of the genes encoding tumor antigens on the surface of tumor cells and enhance the activity of tumor-killing T cells against those tumor cells. Vaccines made from monoclonal antibodies combined with tumor cells may help the body build an effective immune response to kill tumor cells. Giving atezolizumab, guadecitabine, and CDX-1401 vaccine may work better than CDX-1401 alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.

NCT ID: NCT03205176 Completed - Breast Cancer Clinical Trials

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Start date: June 30, 2017
Phase: Phase 1
Study type: Interventional

This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.

NCT ID: NCT03203993 Terminated - Ovarian Cancer Clinical Trials

China Ovarian Cancer BRCA Testing Study

CRONUS
Start date: January 31, 2018
Phase:
Study type: Observational

This is a prospective, multi-center, observational study, the primary objective is to evaluate the prevalence of gBRCA/sBRCAm in newly diagnosed ovarian cancer patients and explore ovarian cancer treatment outcomes of different BRCAm status

NCT ID: NCT03199586 Completed - Breast Cancer Clinical Trials

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Start date: December 21, 2017
Phase: Phase 1
Study type: Interventional

Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.